Radiopharmaceuticals for myocardial infarct imaging: a clinical comparison of 99Tcm-pyrophosphate and 99Tcm-dimethylaminomethylene diphosphonate
| Autor: | A M Millar, R. Grayshan, A L Muir, Derek Bell |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
medicine.medical_specialty
Pathology Technetium Tc 99m Pyrophosphate Sternum Myocardial Infarction chemistry.chemical_element Technetium Pyrophosphate chemistry.chemical_compound Internal medicine medicine Organometallic Compounds Humans Radiology Nuclear Medicine and imaging In patient cardiovascular diseases Myocardial infarction Radionuclide Imaging Aged Rib cage Diphosphonates business.industry General Medicine Organotechnetium Compounds Middle Aged medicine.disease Diphosphates Normal bone chemistry cardiovascular system Cardiology business |
| Zdroj: | The British journal of radiology. 61(727) |
| ISSN: | 0007-1285 |
| Popis: | 99Tcm-pyrophosphate (PYP) has been shown to concentrate in acutely damaged myocardium (Bonte et al, 1974). This has resulted in myocardial infarct imaging with 99Tcm-PYP becoming an established technique in nuclear medicine (Bruno et al, 1976; Parkey et al, 1976). The technique is of value in patients in whom the diagnosis of acute myocardial infarction is uncertain as a result of equivocal changes in the electrocardiogram or cardiac enzymes. A major limitation, however, is the uptake of 99Tcm-PYP into bone which can result in visualization of the myocardial infarct being obscured by activity in the overlying ribs and sternum. In an investigation of new 99Tcm-labelled diphosphonates for skeletal imaging, 99Tcm-dimethylaminomethylene diphosphonate (DMAD) was found to exhibit the highest abnormal/ normal bone ratio (Subramanian et al, 1983). This was shown to be a consequence of low uptake in normal bone rather than high uptake in the lesions. If 99Tcm-DMAD was to concentrate in acutely infarcted myocardium... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|